Irritable Bowel Syndrome Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight

DelveInsight's "Irritable Bowel Syndrome Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Irritable Bowel Syndrome, historical and forecasted epidemiology as well as the Irritable Bowel Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Unlock detailed insights into the Irritable Bowel Syndrome Market by downloading the comprehensive report from DelveInsight @ Irritable Bowel Syndrome Treatment Market Size- https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Irritable Bowel Syndrome Market Report
• In November 2024:- EP Plus Group- The objective of this randomized, double-blind, placebo-controlled study is to evaluate the effectiveness of Skal Pro in alleviating symptoms, enhancing stool consistency, improving quality of life, and addressing psychological distress in individuals diagnosed with irritable bowel syndrome (IBS), as compared to those who receive no intervention.
• The rise in the geriatric population, the increase in the prevalence of gastrointestinal diseases and disorders such as alteration of bowel habits and abdominal pain, the surge in level of stress, and unhealthy diet are the major factors that drive the growth of the irritable bowel syndrome treatment market.
• As per the American College of Gastroenterology (2023), irritable bowel syndrome is common and affects about 5% of the population or about 1 in 20 people in the US.
• As per Cleveland Clinic (2023), it has been estimated that about 10─15% of the adult population in the United States have irritable bowel syndrome. However, only 5─7% receive an irritable bowel syndrome diagnosis. It is the most common disease that gastroenterologists diagnose.
• As per Breen-Lyles et al. (2023), the mean irritable bowel syndrome symptom severity score in Rome IV patients was significantly higher than in Rome III criteria.
• As per Jean-Marc et al. (2023), the severity-specific prevalence of irritable bowel syndrome in France was 31.3% for the moderately severe form and 68.7% for the severe form.
• The leading Irritable Bowel Syndrome Companies such as Redhill Biopharma, Forest Pharmaceuticals, Inc., Bausch Health, and others.
• Promising Irritable Bowel Syndrome Therapies such as Rifaximin, eluxadoline, lubiprostone, linaclotide, and others.

Gain a competitive edge in the Irritable Bowel Syndrome Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Irritable Bowel Syndrome Treatment Drugs-= https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Irritable Bowel Syndrome Epidemiology Segmentation in the 7MM
• Total Irritable Bowel Syndrome Prevalent Cases
• Total Irritable Bowel Syndrome Diagnosed Cases
• Irritable Bowel Syndrome Gender-specific Cases
• Irritable Bowel Syndrome Severity-specific Cases
• Irritable Bowel Syndrome Subtype-specific Cases
• Total Irritable Bowel Syndrome Treated Cases

Irritable Bowel Syndrome Market Insights
Irritable bowel syndrome (IBS) is a complex disorder characterized by motility dysfunction, visceral hypersensitivity, and various contributing factors including genetics, diet, and immune activation. Its diagnosis and management pose significant challenges globally. IBS manifests in diverse forms, classified by predominant stool texture, and imposes a substantial burden on healthcare systems worldwide. In the United States alone, direct medical costs associated with IBS reach up to USD 10 billion annually, exacerbated by high healthcare resource utilization and regional disparities in testing and treatment approaches.

Discover key developments and opportunities in the Irritable Bowel Syndrome Market. Click here to learn more from DelveInsight's latest report @ Irritable Bowel Syndrome Market Size- https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Irritable Bowel Syndrome Marketed Drugs
• VIBERZI/TRUBERZI (eluxadoline): Abbvie
VIBERZI (eluxadoline) is a new class of medication acting on local receptors in the gastrointestinal tract. It improves diarrhea and abdominal pain by interacting with mu- and delta opioid receptors in the intestine to slow gastrointestinal motility and reduce visceral pain. Activation of the mu-receptor reduces diarrhea, while antagonism of the delta-receptor enhances the analgesic activity and reduces the risk of constipation.

• LINZESS/CONSTELLA (linaclotide): Ironwood Pharmaceuticals/ Abbvie/ Astellas Pharma
Linaclotide is a guanylate cyclase-C agonist that is thought to work in two ways based on nonclinical studies. It binds to the guanylate cyclase-C receptor locally within the intestinal epithelium. Activation of guanylate cyclase-C results in increased intestinal fluid secretion, accelerated transit, and a decrease in the activity of pain-sensing nerves in the intestine. In the United States, Ironwood and AbbVie co-develop and co-commercialize LINZESS to treat adults with IBS-C. In Europe, AbbVie markets linaclotide under the brand name CONSTELLA for treating adults with moderate-to-severe IBS-C.

Irritable Bowel Syndrome Emerging Drugs
• BEKINDA (RHB-102): RedHill Biopharma
RHB-102 is an investigational, once-daily, bi-modal release, oral formulation of ondansetron, a leading member of the family of 5-HT3 serotonin receptor inhibitors intended to treat nausea, vomiting, and diarrhea symptoms experienced in some people suffering from acute gastroenteritis, gastritis, and irritable bowel syndrome with diarrhea (IBS-D).

• Blautix (MRx1234): 4D pharma
Blautix (MRx1234) is a single-strain live biotherapeutic product (LBP), being developed as a treatment for both IBS-C and IBS-D and has the potential to become the first-ever disease-modifying therapy suitable for all irritable bowel syndrome patients regardless of clinical subtype. Blautix has a unique metabolism, consuming hydrogen and producing acetate, which promotes bacterial cross-feeding of the microbiota increasing diversity and stability, two attributes that have been demonstrated to be decreased in patients with irritable bowel syndrome compared to healthy controls.

Irritable Bowel Syndrome Therapeutics Market
There are five drugs approved for irritable bowel syndrome in the United States, namely VIBERZI (eluxadoline), LINZESS (linaclotide), IBSRELA (tenapanor), TRULANCE (plecanatide), and XIFAXAN (rifaximin). Market access and reimbursement options can differ depending on regulatory status, the size of the target population, the setting of care, unmet needs, the magnitude of incremental benefit claims, and costs.

Download DelveInsight's Irritable Bowel Syndrome Market report today and stay ahead in this rapidly evolving field. @ Irritable Bowel Syndrome Clinical Trials- https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Irritable Bowel Syndrome Market Report
• Coverage- 7MM
• Irritable Bowel Syndrome Companies- Redhill Biopharma, Forest Pharmaceuticals, Inc., Bausch Health, and others.
• Irritable Bowel Syndrome Therapies- rifaximin, eluxadoline, lubiprostone, linaclotide, and others.
• Irritable Bowel Syndrome Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Irritable Bowel Syndrome Unmet Needs, KOL's views, Analyst's views, Irritable Bowel Syndrome Market Access and Reimbursement

Download the report to understand which factors are driving Irritable Bowel Syndrome Market Trends @ Irritable Bowel Syndrome Market Trends- https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1 Key Insights
2 Report Introduction
3 Irritable Bowel Syndrome Market Overview at a Glance
4 Epidemiology and Market Methodology
5 Executive Summary of Irritable Bowel Syndrome
6 Disease Background and Overview
7 Epidemiology and Patient Population
8 Patient Journey
9 Key Endpoints in Irritable Bowel Syndrome Clinical Trials
10 Emerging Therapies
11 Marketed Therapies
12 Irritable Bowel Syndrome: The 7MM Analysis
13 Market Access and Reimbursement
14 KOL Views
15 SWOT Analysis
16 Unmet Needs
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer

List of Top Selling Market Research Reports in 2024

carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
fabry disease market- https://www.delveinsight.com/report-store/fabry-disease-market
gene therapy in cns disorder market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
surgical lasers market- https://www.delveinsight.com/report-store/surgical-lasers-market
transcatheter treatment market - https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
scoliosis market - https://www.delveinsight.com/report-store/scoliosis-market
stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
vitreoretinal surgery devices market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
lymphoedema market- https://www.delveinsight.com/report-store/lymphedema-market
nk cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
mouth neoplasms market- https://www.delveinsight.com/sample-request/mouth-neoplasms-market
somatotropin deficiency market - https://www.delveinsight.com/report-store/somatotropin-deficiency-market
meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
seltorexant drug market- https://www.delveinsight.com/report-store/major-depressive-disorder-market
surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
antibody drug conjugate market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
skin neoplasm market- https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market
asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.